These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 25140577)

  • 1. Clinical significance of 2 h plasma concentrations of first-line anti-tuberculosis drugs: a prospective observational study.
    Prahl JB; Johansen IS; Cohen AS; Frimodt-Møller N; Andersen ÅB
    J Antimicrob Chemother; 2014 Oct; 69(10):2841-7. PubMed ID: 25140577
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Isoniazid, rifampicin and pyrazinamide plasma concentrations 2 and 6 h post dose in patients with pulmonary tuberculosis.
    Fahimi F; Tabarsi P; Kobarfard F; Bozorg BD; Goodarzi A; Dastan F; Shahsavari N; Emami S; Habibi M; Salamzadeh J
    Int J Tuberc Lung Dis; 2013 Dec; 17(12):1602-6. PubMed ID: 24200276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A UPLC-MS-MS method for the simultaneous quantification of first-line antituberculars in plasma and in PBMCs.
    Baietto L; Calcagno A; Motta I; Baruffi K; Poretti V; Di Perri G; Bonora S; D'Avolio A
    J Antimicrob Chemother; 2015 Sep; 70(9):2572-5. PubMed ID: 26066583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of anti-tuberculosis drugs in Venezuelan children younger than 16 years of age: supportive evidence for the implementation of revised WHO dosing recommendations.
    Verhagen LM; López D; Hermans PW; Warris A; de Groot R; García JF; de Waard JH; Aarnoutse RE
    Trop Med Int Health; 2012 Dec; 17(12):1449-56. PubMed ID: 23094704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic exposure to rifampicin in patients with tuberculosis and advanced HIV disease during highly active antiretroviral therapy in Burkina Faso.
    Saleri N; Dembélé SM; Villani P; Carvalho AC; Cusato M; Bonkoungou V; Nacanabo R; Kouanda S; Comelli M; Regazzi M; Matteelli A
    J Antimicrob Chemother; 2012 Feb; 67(2):469-72. PubMed ID: 22028201
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients.
    McIlleron H; Wash P; Burger A; Norman J; Folb PI; Smith P
    Antimicrob Agents Chemother; 2006 Apr; 50(4):1170-7. PubMed ID: 16569826
    [TBL] [Abstract][Full Text] [Related]  

  • 7. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
    API Consensus Expert Committee
    J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rifampicin and Isoniazid Maximal Concentrations are Below Efficacy-associated Thresholds in the Majority of Patients: Time to Increase the Doses?
    Trentalange A; Borgogno E; Motta I; Antonucci M; Pirriatore V; Costa C; Rossi G; Barco A; De Nicolò A; Piccioni P; D'Avolio A; Bonora S; Di Perri G; Calcagno A
    Int J Antimicrob Agents; 2021 Mar; 57(3):106297. PubMed ID: 33539932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distribution of plasma concentrations of first-line anti-TB drugs and individual MICs: a prospective cohort study in a low endemic setting.
    Niward K; Davies Forsman L; Bruchfeld J; Chryssanthou E; Carlström O; Alomari T; Carlsson B; Pohanka A; Mansjö M; Jonsson Nordvall M; Johansson AG; Eliasson E; Werngren J; Paues J; Simonsson USH; Schön T
    J Antimicrob Chemother; 2018 Oct; 73(10):2838-2845. PubMed ID: 30124844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cure of tuberculosis despite serum concentrations of antituberculosis drugs below published reference ranges.
    Meloni M; Corti N; Müller D; Henning L; Gutteck U; von Braun A; Weber R; Fehr J
    Swiss Med Wkly; 2015; 145():w14223. PubMed ID: 26700218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of food on the pharmacokinetics of first-line anti-TB drugs in treatment-naive TB patients: a randomized cross-over trial.
    Saktiawati AM; Sturkenboom MG; Stienstra Y; Subronto YW; Sumardi ; Kosterink JG; van der Werf TS; Alffenaar JW
    J Antimicrob Chemother; 2016 Mar; 71(3):703-10. PubMed ID: 26661397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of dried blood spot sampling for pharmacokinetic research and therapeutic drug monitoring of anti-tuberculosis drugs in children.
    Martial LC; Kerkhoff J; Martinez N; Rodríguez M; Coronel R; Molinas G; Roman M; Gomez R; Aguirre S; Jongedijk E; Huisman J; Touw DJ; Pérez D; Chaparro G; Gonzalez F; Aarnoutse RE; Alffenaar JW; Magis-Escurra C
    Int J Antimicrob Agents; 2018 Jul; 52(1):109-113. PubMed ID: 29751121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral bioavailability of rifampicin, isoniazid, ethambutol, and pyrazinamide in a 4-drug fixed-dose combination compared with the separate formulations in healthy Chinese male volunteers.
    Xu J; Jin H; Zhu H; Zheng M; Wang B; Liu C; Chen M; Zhou L; Zhao W; Fu L; Lu Y
    Clin Ther; 2013 Feb; 35(2):161-8. PubMed ID: 23410999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intrapulmonary Pharmacokinetics of First-line Anti-tuberculosis Drugs in Malawian Patients With Tuberculosis.
    McCallum AD; Pertinez HE; Else LJ; Dilly-Penchala S; Chirambo AP; Sheha I; Chasweka M; Chitani A; Malamba RD; Meghji JZ; Gordon SB; Davies GR; Khoo SH; Sloan DJ; Mwandumba HC
    Clin Infect Dis; 2021 Nov; 73(9):e3365-e3373. PubMed ID: 32856694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosis.
    Ribera E; Azuaje C; Lopez RM; Domingo P; Curran A; Feijoo M; Pou L; Sánchez P; Sambeat MA; Colomer J; Lopez-Colomes JL; Crespo M; Falcó V; Ocaña I; Pahissa A
    J Antimicrob Chemother; 2007 Apr; 59(4):690-7. PubMed ID: 17307771
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic drug monitoring in the treatment of tuberculosis patients.
    Magis-Escurra C; van den Boogaard J; Ijdema D; Boeree M; Aarnoutse R
    Pulm Pharmacol Ther; 2012 Feb; 25(1):83-6. PubMed ID: 22179055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subtherapeutic concentrations of first-line anti-TB drugs in South African children treated according to current guidelines: the PHATISA study.
    Hiruy H; Rogers Z; Mbowane C; Adamson J; Ngotho L; Karim F; Gumbo T; Bishai W; Jeena P
    J Antimicrob Chemother; 2015 Apr; 70(4):1115-23. PubMed ID: 25505005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simultaneous determination of first-line anti-tuberculosis drugs and their major metabolic ratios by liquid chromatography/tandem mass spectrometry.
    Song SH; Jun SH; Park KU; Yoon Y; Lee JH; Kim JQ; Song J
    Rapid Commun Mass Spectrom; 2007; 21(7):1331-8. PubMed ID: 17340570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of anti-TB drugs in Malawian children: reconsidering the role of ethambutol.
    Mlotha R; Waterhouse D; Dzinjalamala F; Ardrey A; Molyneux E; Davies GR; Ward S
    J Antimicrob Chemother; 2015; 70(6):1798-803. PubMed ID: 25759035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efavirenz, tenofovir and emtricitabine combined with first-line tuberculosis treatment in tuberculosis-HIV-coinfected Tanzanian patients: a pharmacokinetic and safety study.
    Semvua HH; Mtabho CM; Fillekes Q; van den Boogaard J; Kisonga RM; Mleoh L; Ndaro A; Kisanga ER; van der Ven A; Aarnoutse RE; Kibiki GS; Boeree MJ; Burger DM
    Antivir Ther; 2013; 18(1):105-13. PubMed ID: 23043067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.